Osimertinib Tablets

A drug used to treat adults with some types of non-small cell lung cancer that have certain mutations (changes) in the EGFR gene. It is also being studied in the treatment of other types of cancer. Osimertinib mesylate blocks certain proteins made by the mutated EGFR gene, which may help keep cancer cells from growing and may kill them. It is a type of tyrosine kinase inhibitor. Also called Tagrisso. US Brand Name(s): Tagrisso. FDA Approved Yes

Osimertinib, sold under the brand name Tagrisso, is a medication used to treat non-small-cell lung carcinomas with specific mutations. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor. Osimertinib was approved for medical use in the United States in November 2015, and in the European Union in February 2016.

Osimertinib mesylate is approved to treat: Non-small cell lung cancer in adults whose tumors have certain EGFR gene mutations. Osimertinib mesylate is also being studied in the treatment of other types of cancer.